Dynamic regulation of innate immunity by ubiquitin and ubiquitin-like proteins  by Liu, Xing et al.
Survey
Dynamic regulation of innate immunity by ubiquitin and
ubiquitin-like proteins
Xing Liu, Qiang Wang, Wei Chen, Chen Wang *
State Key Laboratory of Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences,
Shanghai 200031, China
Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 559
2. The conjugation machinery of ubiquitin and ubiquitin-like proteins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 560
3. The PAMP-PRR system. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 561
4. Regulatory roles of ubiquitin in TLRs signaling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 561
4.1. Activation of protein kinases by non-K48-linked polyubiquitin chains . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 562
4.2. Regulated degradation of signaling proteins via K48-linked polyubiquitin in TLR signaling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 563
4.3. Emerging role of the ubiquitin-like proteins in TLR signaling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 564
5. Regulatory roles of ubiquitin in RLRs signaling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 564
5.1. Roles of the non-K48-linked polyubiquitin chains in RLR signaling. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 564
5.2. Regulated degradation of the RLR signaling proteins via K48-linked polyubiquitin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 566
5.3. Critical role of the ubiquitin-like proteins in RLRs signaling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 566
6. Emerging role of ubiquitin in NLRs signaling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 567
7. Conclusions and prospects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 567
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 568
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 568
1. Introduction
Innate immunity is the ﬁrst line of host defense against
microbial infection. The past two decades have witnessed the
establishment and elaboration of a new paradigm of the innate
immunity. Generally, pathogen-associated molecular patterns
(PAMPs) are sensed by pattern recognition receptors (PRRs),
which then trigger the immediate host responses to restrict and
contain the microbial infections. In the meantime, cytokines and
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chemokines are induced to initiate the adaptive immunity,
mobilizing immune cells to control and eliminate pathological
infections. Given the critical balances of the PRR effector functions
(immunity vs. inﬂammation, survival vs. apoptosis, proliferation
vs. cancer), they are subjected to multiple layers of positive and
negative protein post-translational modiﬁcations (PTMs). Dozens
of critical signaling proteins have been characterized in vitro and
in vivo to mediate the PRR signaling pathways. Notably, strong
evidence is accumulating that these signaling proteins are
dynamically modulated by the protein posttranslational modiﬁca-
tions (phosphorylation, acetylation, ubiqtination, SUMOylation,
ISGylation), thus ﬁne-tuning the strength and duration of the
innate immune responses, in the particular context of host-
microbe interactions. Interestingly, ubiquitin and ubiquitin-like
proteins (Ubls) are emerging as the critical and versatile molecular
signatures for orchestrating the appropriate innate immune
responses.
Readers are referred to the recent excellent reviews on the
ubiquitin system [1–3] and the signaling and functions of the PRR
system [4–6]. In this review, we will ﬁrst introduce some key
concepts about these two systems, and then focus on the
regulatory cross-talks between these two systems, highlighting
the latest advance on the functions and regulatory mechanisms of
the ubiquitin and the Ubls toward the PRR signaling.
2. The conjugation machinery of ubiquitin and
ubiquitin-like proteins
Post-translational modiﬁcations (PTM) dynamically regulate
the activity and/or broaden the functional spectrum of a given
substrate protein, in response to speciﬁc signals of the biological
actions. Ubiquitin (76 aa) was initially characterized as a label for
proteasome-dependent degradation of the substrate proteins [7].
Ubiquitination is a ATP-dependent enzymatic cascade reaction,
involving three classes of enzymes termed E1 (ubiquitin-activating
enzyme), E2 (ubiquitin-conjugating enzyme) and E3 (ubiquitin
ligase), which forms a stable isopeptide bond between the
ubiquitin C-terminal glycine residue and the e-amino group of
the acceptor lysine residues of the target proteins [8,9] (Fig. 1).
Ubiquitination is reversed by the deubiquitination enzymes
(DUBs) [10].
Normally, ubiquitin is sequentially conjugated onto one or
multiple lysine residues in the target proteins. Although there is
some degree of selectivity of the modiﬁcation sites, most
substrate proteins are modiﬁed on multiple surface lysine
residues simultaneously. Importantly, ubiquitin per se contains
7 lysine residues (K6, K11, K27, K29, K33, K48 & K63), which makes
it able to branch further by conjugating more ubiquitins. So
for a given lysine residue, it could accept either one ubiquitin
moiety (monoubiquitintion) or ubiquitin chains (polyubiquitina-
tion). Furthermore, recent studies reveal the ‘‘head-to-tail’’
linear polyubiquitin chain, in which the a-amino group of the
N-terminal methionine of an ubiquitin is served as the acceptor
site [11].
The wealth of the ubiquitin linkages as potential signals, gives
rise to the distinct functional outcomes of the modiﬁed proteins.
For example, K48-linked polyubiquitin is recognized by 26S
proteasome, and thus signals protein degradation. Recent mecha-
nistic studies suggest that additional proteins are actively involved
in the determination of the polyubiquitin linkage [12,13].
Strikingly, the NEMO protein is reported to be modiﬁed in vivo
by linear-, K27- and K29-linked polyubiquitin chains under
different physiological or pathological conditions (see below)
[14–16]. It is thus a great challenge to monitor the dynamic
formation of the various polyubiquitin chains, and understand
their cognate functional consequences.
Ubiquitin-like proteins (Ubls) represent a growing list of
modiﬁers, which are homologous to ubiquitin and display similar
three-dimensional structures. These include interferon-stimulated
gene-15 (ISG15, also known as ubiquitin cross-reactive protein),
small ubiquitin-like modiﬁer (SUMO), NEDD8 et al. Biochemically,
Ubls are processed, activated, conjugated and deconjugated by a
Fig. 1. The conjugation systems of ubiquitin (Ub) and ubiquitin-like proteins (Ubls). The conjugation processes of Ub or Ubls are ATP-dependent enzymatic cascade reactions,
involving three classes of enzymes termed activating enzyme E1, conjugating enzyme E2 and E3 ligase. Ub or Ubl is ﬁrstly activated by E1 in energy-dependent manner, which
leads to the formation of UbE1 (or Ubl-E1) high-energy thioester. Then through the interaction between UbE1 (or Ubl-E1) and the relevant E2, activated Ub or Ubl is
transferred to the corresponding E2. Finally, Ub or Ubl is targeted to the speciﬁc substrate recognized by E3 ligases. In addition, the conjugation of Ub or Ubls is a dynamic
process, which is reversed by a family of deconjugation enzymes. The corresponding E1, E2, E3 and deconjugation enzymes, respectively for ubiquitination, ISGylation and
SUMOylation, are listed on the diagram.
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different set of enzymes, analogous to that for ubiquitin [17]
(Fig. 1). For example, ISG15 (ﬁrst reported in 1978) contains two
ubiquitin-like domains linked by a hinge, and the C-terminal
LRLRGG motif is responsible for its conjugating onto target
proteins. ISG15 and its E1 activating enzyme Ube1L, E2 conjugating
enzyme UbcH8, E3 ligase Herc5 are all robustly induced upon viral
infection or lipopolysaccharide (LPS) treatment, causing the
ISGylation of a wide spectrum of proteins [18–22]. The functional
consequences of ISGylation are currently under intensive investi-
gation. Apparently, ISGylation does not promote protein degrada-
tion, whereas it is critical for host antiviral actions (see below).
SUMO is ubiquitously expressed throughout the eukaryotic
cells and three paralogs (SUMO-1, SUMO-2, SUMO-3) have been
found in vertebrates. Ubc9 is the conjugating enzyme for SUMO
[23]. Sequence alignment reveals that SUMO-2 and SUMO-3 are
almost identical (97% identical), whereas SUMO-1 is largely
diverged (50% identical to SUMO-2/3). SUMO-4 was recently
proposed as a new member of this family, which might play
some regulatory role in diabetes. SUMOylation is critical for
modulating the protein activity, stability and sub-cellular
localization during signal transductions [24,25]. Interestingly,
SUMOylation could promote or antagonize the ubiquitination of
a given substrate, depending on the topology of the modiﬁcation
sites. For example, SUMOylation of HIF1a induced by hypoxia
leads to its ubiquitination and degradation, whereas SUMO-1
modiﬁed IkBa is resistant to ubiquitin-mediated degradation
[26,27].
3. The PAMP-PRR system
As molecular switches that register microbial infection, an array
of germline-encoded pattern recognition receptors (PRRs) are
engaged to detect the invariant microbial motifs named pathogen-
associated molecular patterns (PAMPs). Toll-like receptors (TLRs)
resides in the plasma membrane and/or endosome, whereas RIG-I-
like receptors (RLRs) and Nod-like receptors (NLRs) localize in the
cytoplasm.
Signaling transduced from these upstream receptors leads
to the activation of a serial of key transcriptional factors including
NF-kB, interferon-regulatory factors (IRFs) and activator protein 1
(AP-1), which coordinate to induce the expression of a broad range
of genes against pathogens infection (Fig. 2). The ultimate outcome
of infection depends on the timing and efﬁciency of both host and
microbe to achieve supremacy. Excessive activation of the PRR
signaling pathways could cause the inﬂammatory and autoim-
mune diseases. Notably, ubiquitin and Ubls are indispensable for
the manifold spatial and/or temporal modulations of the innate
immune signalings.
4. Regulatory roles of ubiquitin in TLRs signaling
To date, 13 members of the TLR family have been identiﬁed in
mammals and each could recognize distinct PAMPs [28]. For
example, TLR4 recognizes lipopolysaccharide (LPS) from gram-
negative bacteria, whereas TLR7 senses viral single strand RNA
Fig. 2. The PAMP-PRR Signaling Network. Toll-like receptors (TLRs) (A), RIG-I-like receptors (RLRs) (B) and Nod-like receptors (NLRs) (C) are major classes of PRRs. Once
engaged with the speciﬁc conserved microbial signature molecules (PAMPs), PRRs would undergo the conformational change and activate intracellular signaling cascades. As
for TLRs, RLRs or Nod1/2 of NLRs; their priming leads to the converging and/or characteristic activation of the key transcriptional factors, including NF-kB, interferon-
regulatory factors (IRFs) and activator protein 1 (AP-1). As a result, cytokines and chemokines are induced to generate the anti-microbial status locally, and mobilize immune
cells for further eliminating pathological infections. In addition, most NLRs trigger the assembly of multiple-protein complex named inﬂammasome, which is comprised of
NLR, ASC, and caspase-1. Subsequently, active caspase-1 processes the precursors of IL-1b and IL-18 into their mature forms.
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(ssRNA). Based on their subcellular localizations, TLRs could be
classiﬁed into two categories, one on the cell surface (TLR1, TLR2
and TLR4) and another in membrane of the intracellular
compartments (TLR3, TLR7/TLR8, and TLR9). The former mainly
senses the invariant component of the extracellular bacteria,
whereas the latter is capable of detecting viral nucleic acids (Fig. 3).
4.1. Activation of protein kinases by non-K48-linked
polyubiquitin chains
TLRs trigger the recruitment of MyD88 via its Toll-interleukin 1
receptor (IL-1R) homology (TIR) domain, which in turn recruits
IRAK4 and IRAK1. IRAK4 then activates IRAK-1 by phosphorylation
Fig. 3. Role of Ub and Ubls in the TLR signaling pathways. Upon engaging the cognate ligands, TLR4/7/8/9 trigger the recruitment of MyD88, IRAK4 and IRAK1 via its Toll-
interleukin 1 receptor (IL-1R) homology (TIR) domain to initiate the MyD88-dependent pathway. In turn, IRAK4 phosphorylates and activates IRAK-1, which dissociates the
IRAKs from MyD88, and causes them to interact with TRAF6, a ubiquitin E3 ligase. Together with Ubc13 and Uev1A, TRAF6 catalyzes the formation of K63-linked
polyubiquitin chains and activates the downstream kinase complexes. As for TLR4 signaling, polyubiquitin chains catalyzed by TRAF6 serve as the anchoring platform for TAK
complex and IKK complex, which leads to the activation of NF-kB and the induction of proinﬂammatory cytokines. For TLR7/8/9 signaling, the polyubiquitin chains recruit
protein complex including TRAF6, TRAF3, IKKa, and IRF7, leading ultimately to the induction of type I IFNs and ISGs (interferon-inducible genes), besides the activation of NF-
kB. TANK could suppress the TRAF6-mediated ubiquitination, whereas mitochondrial protein MARCH5 could release this inhibitory effects of TANK by catalyzing the
polyubiquitination of TANK. Similarly, SUMO-1 modiﬁcation of TANK relieves its repression on TLR signaling. On the other hand, activation of TLR3/4 could also recruit the
adaptor protein TRIF to elicit MyD88-independent/TRIF-dependent pathway. TRIF interacts with both RIP1 and TRAF3, which ultimately leads to the activation of NF-kB or IRF3,
respectively. RIP1 mediated NF-kB activation requires targeting K63-linked polyubiquitin chains onto RIP1. This facilitates the recruitment and activation of TAK1 and IKK
complexes. In contrast, the attenuation or termination of these TLR signalings is achieved by the proteasome-mediated degradation of the signaling proteins, catalyzed by the
corresponding E3 ligases.
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[29,30]. As a result, the IRAKs dissociate from MyD88 and interact
with TRAF6, an ubiquitin E3 ligase. Together with Ubc13 and
Uev1A, TRAF6 catalyzes the formation of lysine 63(K63)-linked
polyubiquitin chains, which recruits and activates the TAK1 (TGF-
b activated kinase 1), TAB1, TAB2/3 kinase complex [31]. Then,
phosphorylation of the IKK complex and the MKK6 by TAK1 leads
to the NEMO-dependent activation of the NF-kB canonical
pathway and the activation of the JNK-p38 kinase pathway,
respectively [31,32] (Fig. 3).
It was intriguing how K63-linked polyubiquitin modulates
protein kinase activity. In vain was it to conﬁrm that TAK1 or its
associated proteins were covalently modiﬁed by ubiquitin. This
enigma is resolved by a surprising observation that the free K63-
linked polyubiquitin chains (catalyzed by TRAF6) are not
conjugated to any target proteins [33]. Instead, TAB2 is a novel
receptor for the K63-linked polyubiquitin chain, which directly
activates TAK1. However, the speciﬁc molecular mechanism still
awaits structural analysis of the protein complex.
TANK is a potent negative regulator of the canonical NF-kB
activation, via suppression of the TRAF6-catalyzed poly-ubiquiti-
nation [34]. Our recent study reveals that mitochondrial E3
ubiquitin ligase MARCH5 positively modulates TLR signaling by
targeting and catalyzing the K63-linked polyubiquitination of
TANK [35]. Consequently, the polyubiquitination of TANK releases
the inhibitory effects of TANK toward TRAF6. This directly links
the mitochondrion to regulate TLR signaling, providing a new
perspective of mitochondrion in innate immunity.
The IKK complex was identiﬁed as a high-molecular-weight
complex. It is composed of two related catalytic subunits, IKKa and
IKKb, and a regulatory subunit, NF-kB essential modiﬁer (NEMO)
[36,37]. Although NEMO does not display catalytic activity, it is
essential for the activation of the canonical NF-kB pathway [38,39].
In vitro experiment showed that puriﬁed IKKa or IKKb together
with NEMO could form IKK complex without the kinase activity,
which indicated that additional factors or posttranslational
modiﬁcations may be required for the formation of a functional
IKK complex. The earlier study implicated a regulatory role of the
K63-linked polyubiquitin chains for IKK activation [32]. This
represents the ﬁrst case of the kinase activation by polyubiquitin
chains. Recent studies proposed that NEMO contains a new type of
bipartite ubiquitin-binding domain (UBD), the UBAN motif
(ubiquitin binding in ABIN and NEMO, a region spanning the
CC2 and leucine zipper domains) and the C-terminal ZF domain,
which recognizes the K63-linked polyubiquitin chain and triggers
IKK activation [40,41]. Recently, it is suggested that recognition of
linear polyubiquitin chains by NEMO is crucial for the activation of
the NF-kB pathway [42]. It remains unknown what is the
functional relationship between the K63-linked and the linear
polyubiquitin chains. Neither is it known how polyubiquitin chains
will trigger the activation of the IKK kinase after NEMO interact
with them. Structural analysis of the compound protein complex
might provide some clues in the future.
Intriguingly, NEMO per se is robustly modiﬁed by the non-K48-
linked polyubiquitin chains [43]. This is also functionally critical
for the IKK activation. In particular, linear polyubiquitination of
NEMO catalyzed by LUBAC (linear ubiquitin assembly complex) is
indispensable for the IKK activation [15]. It is hypothesized that the
IKK complex is responsive to at least two signals for full activation.
The ﬁrst signal is mediated by the interplay between the
polyubiquitin chains and NEMO, and the second signal comes
from the phosphorylation of IKKb by the activated TAK1 kinase
complex. It will be interesting to demonstrate the synergy among
these signals in future studies.
MyD88 is also essential for the production of type I interferons
induced by TLR7/9. It is proposed that engagement of endosomal
TLR7 by ssRNA or TLR9 by CpG-DNA, respectively, results in the
assembly of a multiprotein signalsome in the cytoplasm, which
contains MyD88, TRAF6, IRAK4, IKKa, and the transcription factor
IRF7 (interferon regulatory factor 7) [44–48]. This leads to the
phosphorylation of IRF7, probably by IRAK4 and IKKa. The
activated IRF7 then translocates into the nucleus and induces
the IFN gene transcription (Fig. 3). Phosphatidylinositide-3-kinase
(PI3K) and Bruton’s tyrosine kinase (BTK) have also been implicated
in this pathway [49,50]. As expected, the ubiquitin ligase activity of
TRAF6 is critical for IRF7 activation [47]. Analogous to the NEMO
scenario, it is speculated that the polyubiquitin chains catalyzed
by TRAF6 serve as an anchoring platform, facilitating the
formation of a signal complex. The underlying detailed mechanisms
need further investigation.
TLR3 employs the adaptor protein TRIF for downstream
signaling. TLR4 can also recruit TRIF in response to LPS, indirectly
through interacting with another adaptor called TRAM (TRIF-
related adaptor molecule). Further studies have established that
RIP1 acts as an essential adaptor in TLR3/4 induced NF-kB
activation, which is dependent on TRIF [51,52] (Fig. 3). Interest-
ingly, TLR3/4 agonists could induce the polyubiquitination of RIP1,
which is required for the subsequent IKK activation. Since TRAF6
could bind TRIF, it was believed that TRAF6 might catalyze the
polyubiquitination of RIP1. However, TRAF6 deﬁciency did not
inﬂuence the TRIF-dependent signaling. Recently, Peli1 was
uncovered as a E3 ubiquitin ligase that catalyzes K63-linked
ubiquitination of RIP1, thus promoting the TRIF-dependent Toll-
like receptor signaling [53].
4.2. Regulated degradation of signaling proteins
via K48-linked polyubiquitin in TLR signaling
In resting cells, NF-kB is sequestered in the cytoplasma via
binding to its inhibitor IkBa. Signal-induced degradation of IkBa is
the critical regulatory mechanism for NF-kB activation, which is
initiated upon speciﬁc phosphorylation on the Ser32 and Ser36 of
the N-terminus of IkBa by activated IKK complex. The phosphor-
ylated IkBa can be recognized by the E3 ubiquitin ligase complex
SCF
bTrCP, resulting in K48-linked polyubiquitination and protea-
some-dependent degradation of IkBa [54–56]. This releases NF-kB
to translocate from cytoplasm into nucleus, promoting cognate
gene expression.
In contrast, K48-linked polyubiquitination is most often
employed as an irreversible mechanism to quickly terminate a
given signaling pathway, thus preventing the detrimental effects of
the excessive responses of the host. This mechanism is widely
applied to the regulation of innate immunity.
The E3 ubiquitin ligases Nrdp1 and TRIM38 negatively regulate
the NF-kB signaling by targeting MyD88 and TRAF6 for degradation,
respectively. Nrdp1 directly binds and catalyzes the K48-linked
polyubiquitination of MyD88, causing the proteasome-dependent
degradation of MyD88 [57]. Likewise, TRIM38 promotes the K48-
linked polyubiquitination and degradation of TRAF6, impairing the
sustained NF-kB activation [58]. Consistently, TRIM38 is induced
by TLR agonists, thus acting as a negative feedback regulator in TLR
signaling.
Sustained NF-kB activation is the leading cause of inﬂamma-
tion, autoimmune disease and cancer. One way to terminate its
action is via actively exporting NF-kB to cytoplasm by IkBa, which
has been well established. Another effective way is to directly
terminate NF-kB action inside nucleus, which is recently
substantiated. Initially, SOCS1 was identiﬁed as a binding partner
of p65/RelA, via Ni-NTA afﬁnity chromatography coupled with
mass spectrometry analysis [59]. Functional analysis revealed that
SOCS1 negatively regulates the NF-kB signaling. In addition, LPS
treatment induces SOCS1 and enhances the binding afﬁnity
between SOCS1 and p65/RelA. Mechanistically, SOCS-1, together
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with Elongins B/C and Cul2, signiﬁcantly reduced the stability of
p65/RelA by catalyzing the K48-linked polyubiquitination of p65/
RelA [60]. In contrast, PIN1 could compete with SOCS1 to bind p65/
RelA and prevents the turnover of p65/RelA [59]. Interestingly,
further analysis uncovered that p65/RelA is degraded by the
proteasome in a DNA binding-dependent manner, i.e. p65/RelA
undergoes the ubiquitination-dependent degradation near the
cognate promoters [61]. Paradoxically, SOCS-1 is located mainly in
the cytoplasm, which suggested that an unknown ubiquitin E3
ligase is responsible for catalyzing the nuclear p65/RelA ubiqui-
tination. Recently, the nuclear protein PDLIM2, which belongs to a
large family of LIM proteins, was reported as a negative modulator
of the NF-kB signaling [62]. Consistently, PDLIM2 deﬁciency
results in elevated production of proinﬂammatory cytokines in
response to LPS in vivo. Further studies revealed that PDLIM2
facilitated the translocation of p65/RelA into the PML nuclear
bodies, where PDLIM2 could promote the polyubiquitinaton and
proteasomal degradation of p65/RelA, terminating the nuclear NF-
kB activity. Taken together, two ubiquitin E3 ligases, ECSSOCS1
complex (Elongins B and C, Cul2 and SOCS1) and PDLIM2, have
been identiﬁed to promote the polyubiquitination and subsequent
proteasome-dependent degradation of p65/RelA. However, the
physiological contribution of the two ubiquitin ligase complex
needs further investigation.
4.3. Emerging role of the ubiquitin-like proteins in TLR signaling
PIAS1 (protein inhibitor of activated STAT1) is a putative
candidate of the SUMO E3 ligases. Previously, it was demonstrated
that PIAS1 is a novel negative regulator of the NF-kB signaling,
indicating that SUMOylation could modulate innate immunity
[63]. To corroborate it, a yeast two-hybrid screen ﬁshed out the
SUMO conjugating enzyme Ubc9, which speciﬁcally bound to
IkBa. Further analysis conﬁrmed that SUMO-1 could be conjugat-
ed on to IkBa, and this modiﬁcation is inhibited by the
phosphorylation of IkBa [27]. Interestingly, the SUMOylation
predominantly occurs on the lysine 21 of IkBa, the same residue
for IkBa ubiquitination. As expected, the SUMOylation of IkBa
makes it resistant to the signal-induced degradation, indicating
that SUMOylation and ubiquitination display antagonistic effect.
SUMOylation could promote or antagonize the ubiquitination
of a given substrate, depending on the topology of the modiﬁcation
sites. Unexpectedly, our recent study revealed that NEMO is
modiﬁed by SUMO-3, and this modiﬁcation prevents the access of
CYLD to the IKK complex, thus impairing the negative action of
CYLD, a de-ubiquitinase for NEMO. Ultimately, SUMOylation
synergizes the non-K48-linked polyubiquitination of NEMO and
the activation of IKK. The importance of the SUMOylation of NEMO
is further substantiated by the ﬁndings that the deSUMOylation
enzyme SENP6 attenuates the IKK activation by speciﬁcally
deconjugates the SUMO-3 modiﬁcation of NEMO, which indicates
that ubiquitination and SUMOylation are synergistic in this case
[64].
5. Regulatory roles of ubiquitin in RLRs signaling
In contrast to TLRs that monitor the presence of topologically
extracellular viruses in immune cells, RNA helicases RIG-I (retinoic
acid inducible gene I, also known as Ddx58) and Mda5 (melanoma
differentiation-associated gene 5) have recently been character-
ized as the ubiquitous sensors for detecting cytosolic RNA
viruses during the primary host responses [65,66]. Both helicases
contain two N-terminal caspase recruitment domains (CARD) and
a C-terminal RNA helicase domain. In the resting cells, RIG-I/MDA5
is in the state of auto-inhibition. Upon sensing the viral RNAs,
RIG-I/MDA5 would undergo a conformational change to expose
the N-terminal CARD domains, which in turn recruit MAVS
(also known as IPS1, VISA or Cardif) through CARD homotypic
interactions [67–70]. As a result, a signal complex is formed on the
mitochondrial outer membrane, which includes adaptor proteins
MAVS, TRAF3 and TRADD [71–74]. In the meantime, the Hsp90/
TBK1/IRF3 protein complex is recruited onto mitochondria via
binding to TOM70, a mitochondrial outer-membrane receptor [75–
77]. Interestingly, MAVS and TOM70 co-localize with each other
upon virus infection. This ultimately leads to the activation of the
TANK-binding kinase 1 (TBK1), which then phosphorylates
interferon regulatory factor 3 (IRF3) on a series of Ser/Thr residues
at its C-terminus [78,79]. In turn, IRF3 dimerizes and translocates
into nucleus, which forms a transcriptional enhanceosome
with the coactivator CBP/p300 and induces the early production
of IFN-b and subsequent establishment of the antiviral state
[80,81] (Fig. 4).
Characterization of MAVS linked mitochondria to the intracel-
lular antiviral signaling. In addition, endoplasmic reticulum (ER) is
another essential platform for the signal transduction, as revealed
by the characterization of an ER protein STING [82–84]. STING
deﬁcient cells and mice show severely impaired interferon
production in response to either DNA viruses or RNA viruses
[85]. Notably, the biochemical analysis uncovered that STING
could interact with RIG-I, MAVS, TBK1 as well as IRF3 [83].
However, the underlying mechanism of the STING action remains
to be explored.
5.1. Roles of the non-K48-linked polyubiquitin chains in RLR signaling
Recent studies demonstrate that the E3 ubiquitin ligase TRIM25
(tripartite-motif-containing protein 25) binds to the CARD domain
of RIG-I and catalyzes its K63-linked polyubiquitination on the
lysine 172 residue [86]. This modiﬁcation facilitates MAVS to
interact with RIG-I, serving as a potential mechanism of relaying
activation signal to MAVS signalsome. Further studies reveal that
TRIM25 interacts with the ﬁrst CARD domain of RIG-I and thus
delivers the K63-linked polyubiquitin to the second CARD domain
[87]. Mechanistically, the RIG-I threonine 55 residue (in the ﬁrst
CARD) and lysine 172 residue (in the second CARD) are both critical
for the RIG-I signaling. RIG-I (T55I) is deprived of its binding
activity toward TRIM25, whereas RIG-I (K172R) eliminates its
polyubiquitin chains. Interestingly, the inﬂuenza A virus NS1
protein (non-structural Protein 1, a major virulence factor and
potent inhibitor of RIG-I signaling) has been characterized to target
the RIG-I polyubiquitination [88]. Speciﬁcally, the NS1 directly
binds to TRIM25, suppressing the oligomerization of the latter and
impairing the catalytic activity of TRIM25. In addition, NS1
prevents RIG-I from sensing the viral dsRNAs.
Moreover, LUBAC could modulate the RIG-I signaling pathway
by targeting RIG-I and TRIM25 [89]. On the one hand, LUBAC
interacts with TRIM25 and catalyzes the K48-linked polyubiqui-
tination of TRIM25, causing its proteasome-dependent degrada-
tion. On the other hand, LUBAC interferes with the afﬁnity between
RIG-I and TRIM25, independent of its catalytic activity. Thus, the
functional characterization of NS1 and LUBAC in the RIG-I signaling
underscores the crucial role of TRIM25 in antiviral immunity. In
addition, NEMO has been suggest to be essential for activating
both NF-kB and IRF3 upon viral infection [90,91]; While linear
ubiquitination of NEMO catalyzed by LUBAC could transform
NEMO, to be a negative regulator of RIG-I signaling, as linear
ubiquitinated NEMO disrupts the interaction between MAVS and
TRAF3 [92].
Likewise, RNF135 (also known as Riplet, REUL) was identiﬁed to
potentiate the antiviral responses, via facilitating the K63-linked
polyubiquitination of RIG-I [93,94]. Importantly, RNF135 performs
its action in a TRIM25-independent manner. The analysis of
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RNF135 KO mice conﬁrmed its essential role in the RIG-I activation
in vivo [95]. However, it remains controversial as to the RIG-I
ubiquitination sites catalyzed by RNF135.
Recently, an in vitro cell-free system has been established that
partially recapitulates the RIG-I signaling [96]. It is found that,
when incubating the viral RNA mimics (50-pppRNA) with the
puriﬁed RIG-I, mitochondria and cytosolic extracts, the RIG-I
signaling cascade is fairly activated, as evidenced by the IRF3
dimerization. Interestingly, this in vitro system only works in the
presence of the ubiquitin system. Furthermore, the free K63-linked
polyubiquitin chains per se are recognized by the tandem CARDs of
RIG-I, which is necessary for the RIG-I activation. Consistently, the
other forms of polyubiquitin linkages display no such effect.
Mechanistically, the Threonine 55 residue and lysine 172 residue
of RIG-I are critical for its binding to the K63-linked polyubiquitin
chain. Given the new perspective, it is reasonable to argue that
the unanchored K63-linked polyubiquitin chain, rather than the
putative polyubiquitin modiﬁcation of RIG-I, is functionally
responsible for the RIG-I activation.
Zeng et al. undertook a biochemical approach to explore how
MAVS causes the TBK1 activation [97]. Fractionation of the
cytosolic extracts led to the identiﬁcation of Ubc5 (a E2 ubiquitin
conjugating enzyme) as an essential component for the IRF3
phosphorylation during viral infection. Furthermore, K63-linked
polyubiquitin chains is critical for the IRF3 activation via MAVS.
Importantly, the two ubiquitin-binding domains of NEMO (see
previous sections) are essential for this signal transduction,
implying that NEMO senses the K63-linked polyubiquitin chains
to trigger TBK1 activation. It remains to test whether other
unknown E3 ubiquitin ligases catalyze this process. However, it
could not be formally ruled out that TBK1 per se could also sense
the unanchored polyubiquitin chains.
A new twist is recently proposed that, the ubiquitin E3 ligase
TRIM23 (Triparite motif protein 23) was important for the virus-
induced activation of both IRF3 and NF-kB [14]. Biochemical
analysis reveals that TRIM23 could interact with NEMO and
catalyzes the conjugation of K27-linked polyubiquitin chain onto
NEMO. Similarly, the bacterial IpaH9.8 protein (a E3 ubiquitin
ligase) is also capable of catalyzing the K27-linked polyubiquityla-
tion of NEMO, causing the proteasome-dependent degradation of
NEMO [98]. It is intriguing to test whether the K27-linked
polyubiquitination of NEMO is necessary and sufﬁcient for the
Fig. 4. Role of Ub and Ubls in the RLR signaling pathway. Upon RNA virus infection, RIG-I/MDA5 bind to dsRNA, and undergo dramatic conformational changes. Consequently,
they associate with the adaptor protein MAVS on the outer membrane of mitochondria through CARD-CARD homotypic interaction. In turn, this triggers MAVS to recruit
other signal transduction partners including Tom70, TRAF3 and TBK1. Ultimately, the transcription factor IRF3 is phosphorylated by the activated TBK1, and then translocates
into nucleus to initiate antiviral gene transcription. The K63-linked polyubiquitination of RIG-I and STING as well as the K27-linked polyubiquitination of NEMO are essential
for RLR signal transduction. In contrast, K48-linked polyubiquitination and subsequent degradation of RIG-I, MAVS, STING, TRAF3, TBK1 and IRF3 by RNF125 or c-Cbl, Itch,
RNF5, Triad3A, DTX4 and RAUL respectively, ﬁne-tune the RLR antiviral innate immunity. In addition, ISGylation sustains RLR signaling by targeting RIG-I and IRF3. ISGylation
of RIG-I promotes its K63-linked polyubiquitination; while ISGylation of IRF3 inhibits its K48-linked polyubiquitination and degradation. The function of SUMOylation in RLR
signaling is still controversial.
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antiviral response. Notably, the E3 ubiquitin ligases cIAP1 (cellular
inhibitor of apoptosis protein 1) and cIAP2, ﬁrstly identiﬁed as the
signaling components associated with TRAF2 and TRAF5 in the
TNFRI signaling, were shown to be critical in the RIG-I signaling via
catalyzing the ubiquitination of TRAF3 [99]. Currently, it is a great
challenge to ﬁsh out the real sensors of the non-K48-linked
polyubiquitin chains and understand the structural and functional
relationship among them.
Similarly, the E3 ubiquitin ligases TRIM56 and TRIM32 have
been proposed as positive modulators in STING-dependent IRF3
activation [100,101]. It was suggested that both of the ligases
facilitate the K63-linked polyubiquitination of STING, which is
required for recruitment and activation of TBK1. In contrast, with
an in vitro cell-free system, Tanaka et al. demonstrated that STING
could directly bind and then activate TBK1 in a ubiquitination-
independent manner [102]. Thus, the K63-linked polyubiquitin
chain might have uncharacterized roles for the STING function.
5.2. Regulated degradation of the RLR signaling proteins via K48-
linked polyubiquitin
A striking theme of the RIG-I signaling pathway is that, almost
all of the key signal proteins are negatively regulated by the K48-
linked polyubiquitin, highlighting their critical roles as the hub of
signal integration. This also suggests that the RIG-I signaling must
be terminated timely. Otherwise the effector functions will be
detrimental for the host normal physiology.
RNF125 (RING-type E3 ubiquitin ligase) could catalyze the
polyubiquitination of RIG-I and Mda5, causing their proteasome-
dependent degradation [103]. Notably, RNF125 is up-regulated by
polyI:C treatment, suggesting a negative feedback regulation for
the innate antiviral signaling. In addition, c-Cbl was recently
identiﬁed as another E3 ligase which promotes polyubiquitination
and proteasomal degradation of RIG-I [104]. And this process
depends on phosphorylation of c-Cbl by the immunoglobulin-like
lectin family member Siglec-G induced upon RNA viral infection.
Further investigations will be needed to characterize whether
these ligases function in a spatial or temporal manner to target
RIG-I for ubiquitination.
Interestingly, the mitochondrial protein MAVS was reported to
be modiﬁed by both K48- and K63-linked polyubiquitin. The K63-
linked polyubiqutin chain on the MAVS K500 residue could recruit
IKKe to mitochondria [105]. Unexpectedly, this process negatively
regulates the IFN induction. The relevant E3 ubiquitin ligase and
inhibitory mechanism are unknown. In addition, the poly(rC)
binding protein PCBP1 or PCBP2 functions as an adaptor,
recruiting Itch onto MAVS [106,107]. Itch (AIP4) is a HECT
domain-containing E3 ligase, which thus catalyzes the K48-linked
polyubiquitination of MAVS and attenuates the antiviral signal-
ing. Interestingly, PCBP1 and PCBP2 exhibit distinct expression
patterns, indicating that they might play different roles in the
antiviral response. Indeed, PCBP1 seems to facilitate the
constitutive turnover of the MAVS, whereas PCBP2 is robustly
induced and then promotes the degradation of MAVS in the late
phase of the viral infection [107]. Alternatively, RNF5 was
reported to mediate the degradation of MAVS by promoting the
K48-linked polyubiquitination of MAVS [108]. Notably, RNF5 and
Itch seems to be non-redundant, and they may function in
different phases of viral infection. It is intriguing for future studies
to address the dynamic relationship of the K63- and K48-linked
polyubiquitination on MAVS.
RNF5 could also target STING for K48-linked polyubiquitination
and subsequent degradation [109]. Interestingly, the same lysine
150 of STING was modiﬁed by the K48-linked or K63-linked
polyubiquitin chain, the latter of which was catalyzed by TRIM56
[100,109]. In addition, the ubiquitin ligase Triad3A and DTX4 are
demonstrated to target TRAF3 and TBK1, respectively, for poly-
ubiquitination-dependent proteasomal degradation [110,111].
Likewise, the protein level of the endogenous IRF3 is
dramatically diminished 6–8 h after RNA virus infection. This
phenomenon could be reversed by the proteasome inhibitor
MG132 or Lactacystin, suggesting that IRF3 is degraded in a
proteasome-dependent manner [81,112]. In addition, IRF3 is
phosphorylated on multiple sites when activated. The IRF3 mutant
(K396/398/402/404/405A), which is deprived of the phosphory-
lation sites, becomes resistant to the virus-induced degradation.
Consistently, IRF3 in the TBK1-deﬁcient cells is also unresponsive
to this degradation [112]. Collectively, these observations indicate
that the phosphorylation of IRF3 on the C-terminal Ser/Thr cluster
is a prerequisite for the IRF3 degradation. Indeed, the phosphor-
ylation of IRF3 results in the recruitment of Pin1 and cullin1
[112,113]. Cullin1 is an integral component of the SCF family of
ubiquitin E3 ligase. It remains unknown if the SCF complex
catalyzes the IRF3 K48-linked polyubiquitination. However, it was
shown that Pin1 could promote IRF3 polyubiquitination as well as
the subsequent degradation by proteasome, possibly by inducing a
conformational change of IRF3, since Pin 1 contains an intrinsic
activity of the prolyl isomerase. Alternatively, Yu et al. reported
recently that RAUL (RTA-Associated Ubiquitin Ligase), a HECT
domain E3 ubiquitin ligase, is able to catalyze the K48-linked
polyubiquitination of IRF3 and IRF7 [114]. However, they did not
address whether the RAUL-mediated IRF3 degradation depends on
the phosphorylation of IRF3. Nor did the relationship between Pin1
and RAUL is known. In addition, another study proposed that
TRIM21 could interact with IRF3 and catalyzes its polyubiquitina-
tion [115]. Our study contradicts with this claim [116]. Although
we did ﬁnd that TRIM21 speciﬁcally interacts with IRF3, we
demonstrate that this interaction prevents the access of the
potential E3 ubiquitin ligase to IRF3, thus TRIM21 stabilizes the
IRF3. We think that TRIM21 actually catalyzes its auto-ubiquitina-
tion or the ubiquitination of some regulatory proteins in the IRF3
protein complex.
5.3. Critical role of the ubiquitin-like proteins in RLRs signaling
Besides the ubiquitin-mediated regulation, RIG-I could be
speciﬁcally modiﬁed by SUMO-1 [117]. This modiﬁcation could
facilitate the K63-linked polyubiquitination of RIG-I and potentiate
the antiviral responses. In contrast, IRF3 could be covalently
modiﬁed by SUMO-1 as well as SUMO-2/3 [118]. However, it
remains controversial as to the speciﬁc SUMOylation sites on IRF3
and the functional consequences of the SUMOylated IRF3. Whereas
Kubota et al. proposed that the lysine 152 of IRF3 was the unique
residue of the SUMOylation, which down-regulated the IRF3
transcriptional activity [118], Ran et al. demonstrated that the
lysine 87 is critical for the SUMOylation, which attenuated the
K48-linked polyubiquitination and the subsequent proteasomal
degradation of IRF3 [119]. This discrepancy might arise from the
time windows that either study used to monitor the IRF3
SUMOylation. Or it is worthwhile to explore the speciﬁc SUMO
isoforms in these studies to resolve the apparent inconsistence.
Unexpectedly, IRF3 is also modiﬁed by ISG15, which is robustly
induced by virus infection [120,121]. This ISGylation is not
dependent on the phosphorylation status of IRF3. Our recent
study uncovered that HERC5 catalyzes the ISGylation on the lysine
residue 193, 360 and 366 of IRF3 [120]. This modiﬁcation blocks
the Pin1 and IRF3, thus signiﬁcantly impairing the IRF3 ubiqui-
tination and its proteasome-dependent degradation. So the
ISGylation of IRF3 helps to sustain the IRF3 activation. This claim
is consistent with the in vivo observations that the ISG15-deﬁcient
mice were much easier to succumb to inﬂuenza, herpes and
Sindbis viruses [122].
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6. Emerging role of ubiquitin in NLRs signaling
The Nod-like receptors (NLRs) are another family of the
intracellular PRRs, which is characterized by the presence of the
NOD domain (nucleotide-binding and oligomerization). NLRs also
contain C-terminal leucine-rich repeats (LRRs) and N-terminal
effector binding region, such as the caspase recruitment domains
(CARD), pyrin domain (PYD) or baculovirus inhibitor repeat (BIR)
[123]. Based on the type of the N-terminal domain, NLRs are roughly
divided into three subfamilies: NOD, NLRP and IPAF [124]. NOD1 and
NOD2 are strong activators of the NF-kB signaling [125]. They are
genetically implicated in Crohn’s disease [126]. However, most NLRs
(such as IPAF and NLRP3) are functionally important in procaspase-1
activation catalyzed by the inﬂammasome [125,127] (Fig. 5).
NOD1/2, upon ligands binding, would expose the N-terminal
CARD domains and recruit the serine-threonine kinase RIP2, which
ultimately leads to the NF-kB activation. Interestingly, during this
process, RIP2 simultaneously undergoes both K63-linked and non-
K63-linked polyubiquitination, which respectively recruit the
TAK1 protein complex and the linear ubiquitin chain assembly
complex (LUBAC), thus activating the IKK complex [128–130]
(Fig. 5). RIP2 mutant (K209R) that is deprived of the polyubiquitin
chains, failed to stimulate the NF-kB signaling, when NOD1/2 are
activated [128]. This indicates that the polyubiquitin chains are
essential for the action of RIP2. Similarly, cIAP1 (cellular inhibitor
of apoptosis protein 1) and cIAP2 are recently demonstrated to
catalyze the K63-linked polyubiquitination of Caspase-1 [131]
(Fig. 5). Consistently, cIAP deﬁcient mice displayed a blunted
Caspase-1-dependent inﬂammatory response.
7. Conclusions and prospects
Given the double-edged functions of the anti-microbial
responses, the timing, strength and duration of the innate signaling
Fig. 5. Role of Ub and Ubls in the NLR signaling pathway. Members of NLR family elicit immune responses through activation of NF-kB or formation of caspase-1-activating
inﬂammasomes. During the process, non-degradative polyubiquitination is required for full and efﬁcient NF-kB activation and caspase-1 maturation. The polyubiquitin
chains on RIP2 catalyzed by E3 ligases cIAP1/2 and XIAP, provide the docking sites for the TAK1-TAB2/3 complex and LUBAC, respectively, which results in IKK activation. In
addition, cIAP1/2 contributes to caspase-1 activation by facilitating K63-linked polyubiquitination of caspase-1.
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must be rapidly and appropriately modulated, which ensures that
the microbes are contained and eliminated, whereas the damages to
the host is restricted to the minimum. Like phosphorylation,
ubiquitin have been extensively characterized as the versatile
mechanisms to achieve these ends. In addition, ubiquitin-like
proteins are emerging as novel means to modulate these signalings.
Importantly, it remains to elucidate in detail what are the
functional and physical relationships among these modiﬁcations.
How ubiquitination, SUMOylation and ISGylation perform syner-
gistic and/or antagonistic functions? What are the speciﬁc
signaling signiﬁcances of the different linkages of the ubiquitina-
tion? Is there any general functional and mechanistic theme of the
ISGylation? Will the aberrant action of the ISGylation system leads
to any severe diseases in human?
More work is needed to understand the regulatory processes in
removing the Ub and Ubls in the relevant physiological contexts. In
particular, several critical signaling proteins (MAVS, NEMO, IRF3
et al.) are modiﬁed by many types of the PTMs. However, little is
known about the spatial and temporal dynamics of the modiﬁca-
tions. One possibility is that the modiﬁcations may display cell- or
tissue-speciﬁc functions. Another possibility is that different
stimuli will trigger a different program of modiﬁcations. For
example, DNA damage will induce the NEMO PTM by SUMO-1,
whereas LPS stimuli trigger the NEMO PTM by SUMO-3.
Correspondingly, SENP2 and SENP6 are responsible for the de-
SUMOylation of the former and latter cases of NEMO, respectively.
It is worthwhile to explore the underlying mechanisms of these
interesting discriminations. Single molecular approaches, in
combination with structural analysis of the relevant protein
complex, will be sure to provide more in-depth understanding of
the actions of the Ub and Ubl PTMs. Recently, mitochondrion, ER,
endosome and lysosome are revealed to cooperatively regulate the
anti-microbial signalings. It is intriguing to further address how
the Ub and Ubl PTMs modulate the location and activity of the hub
signal proteins, adjusting the protein networks according to the
extracellular and intracellular contexts.
Taken together, a considerable amount of data is currently
available for the Ub- and Ubls-mediated modiﬁcations in innate
immunity. The great challenge revolves around how to convert the
data into the deep understandings of the innate antimicrobial
mechanisms. New approaches, such as the systematic analysis of
the in vivo modiﬁcations in a time-lapsed manner, will be needed
to bring a holistic picture of the complex cross-talks and intricate
regulations. The resulting insights will provide new therapeutic
strategies and targets for clinically manipulating the pathological
disorders in innate immunity.
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